The efficacy of gabapentin in children of partial seizures and the blood levels
- PMID: 23647918
- DOI: 10.1016/j.braindev.2013.04.006
The efficacy of gabapentin in children of partial seizures and the blood levels
Abstract
Aim: To evaluate the long-term efficacy of gabapentin (GBP) and usefulness of measurement of the blood level for the observation of patients that have partial seizures.
Methods: Thirty patients (20 effective cases and 10 ineffective cases) treated with GBP for the localization related epilepsy had their peak blood levels of GBP. The levels were measured seven time points, one, 6, 12, 18, 24, 30, and 36month after the start of medication. The efficacy of GBP was evaluated at one month after the initiation of medication and every year for 3years, based on the R Ratio and the degree of improvement for the paroxysmal strength and length.
Results: GBP levels were higher in the effective cases than the levels in the ineffective cases 6months after and 1year after the initiation of medication (p<0.05). The level 6months after the start in the effective cases was 5.429±2.384μg/ml (mean±SD), and 5.837±3.217μg/ml after 1year. The cases that were effective for 1year maintained approximately the same efficacy for 3years after the initiation of medication, but there was no correlation between the level and the R Ratio, paroxysmal strength and length.
Conclusions: No precise definition of the therapeutic range was recognized because of no correlation between GBP level and the improvement of clinical manifestations. We recommend the GBP optimal range that is established the range within 3-8μg/ml (mean; 5μg/ml) as therapeutic target without the side effect.
Keywords: Antiepileptic drug; Localization related epilepsy; Optimal range; Paroxysmal strength and length; Response ratio.
Copyright © 2013 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.
Similar articles
-
The use of lamotrigine, vigabatrin and gabapentin as add-on therapy in intractable epilepsy of childhood.Seizure. 2005 Mar;14(2):112-6. doi: 10.1016/j.seizure.2004.12.001. Seizure. 2005. PMID: 15694564
-
[Efficacy, safety and effect on the quality of life of gabapentin in adult epilepsy--results of a prospective open-label quasi naturalistic Hungarian multicenter study (phase human-IV)].Ideggyogy Sz. 2006 Sep 20;59(9-10):361-72. Ideggyogy Sz. 2006. PMID: 17165379 Clinical Trial. Hungarian.
-
Treatment of partial seizures with gabapentin: double-blind, placebo-controlled, parallel-group study.Psychiatry Clin Neurosci. 2006 Aug;60(4):507-15. doi: 10.1111/j.1440-1819.2006.01553.x. Psychiatry Clin Neurosci. 2006. PMID: 16884455 Clinical Trial.
-
[Gabapentin in children and adolescents with epilepsy].Rev Neurol. 2002 Feb 16-28;34(4):384-7. Rev Neurol. 2002. PMID: 12022057 Review. Spanish.
-
[A novel antiepileptic, gabapentin (GABAPEN)].Nihon Yakurigaku Zasshi. 2007 Apr;129(4):299-307. doi: 10.1254/fpj.129.299. Nihon Yakurigaku Zasshi. 2007. PMID: 17435343 Review. Japanese. No abstract available.
Cited by
-
Population pharmacokinetics of gabapentin in healthy Korean subjects with influence of genetic polymorphisms of ABCB1.J Pharmacokinet Pharmacodyn. 2017 Dec;44(6):567-579. doi: 10.1007/s10928-017-9549-6. Epub 2017 Oct 10. J Pharmacokinet Pharmacodyn. 2017. PMID: 29018999
-
Gabapentin add-on treatment for drug-resistant focal epilepsy.Cochrane Database Syst Rev. 2018 Oct 24;10(10):CD001415. doi: 10.1002/14651858.CD001415.pub3. Cochrane Database Syst Rev. 2018. Update in: Cochrane Database Syst Rev. 2021 Jan 12;1:CD001415. doi: 10.1002/14651858.CD001415.pub4. PMID: 30357813 Free PMC article. Updated.
-
Gabapentin add-on treatment for drug-resistant focal epilepsy.Cochrane Database Syst Rev. 2021 Jan 12;1(1):CD001415. doi: 10.1002/14651858.CD001415.pub4. Cochrane Database Syst Rev. 2021. PMID: 33434292 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials